Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

45.58 +0.23 (+0.51%)
Streaming Delayed Price Updated: 10:38 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,328
Open 45.62
Bid (Size) 45.53 (3)
Ask (Size) 45.72 (4)
Prev. Close 45.35
Today's Range 44.62 - 46.13
52wk Range 5.650 - 65.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings For Janux Therapeutics
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+313.61%
+313.61%
1 Month
-6.75%
-6.75%
3 Month
+246.88%
+246.88%
6 Month
+400.33%
+400.33%
1 Year
+222.58%
+222.58%

More News

Read More
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Via InvestorPlace
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
Via Benzinga
Why Janux Therapeutics Stock Is Crushing It This Week
Via The Motley Fool
Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
Via Benzinga
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Why Janux Therapeutics Stock Soared as the Market Sagged Today
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Via The Motley Fool
B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know
Via Benzinga
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
5 Stocks That More Than Doubled In February
Via Talk Markets
Topics Stocks
Exposures US Equities
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
Via The Motley Fool
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
Via Investor's Business Daily
Janux Therapeutics Announces Proposed Public Offering of Common Stock
From Janux Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.